BioPharmSignal logoBioPharmSignal

Biotech News

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa (KNSA)KiniksaEarnings

– ARCALYST ¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC

Related news

KNSAKiniksa2026-07-23 20:01 EST

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026

XFORX4 Pharmaceuticals2026-08-06 20:15 EST

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

CLDXCelldex Therapeutics2026-08-06 20:01 EST

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

REGNRegeneron Pharmaceuticals2026-07-30 10:30 EST

Regeneron Reports Second Quarter 2026 Financial and Operating Results

ARGXArgenx2026-07-23 05:00 EST

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Kiniksa

IL-1 Cardiovascular Franchise Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling. ARCALYST ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine...

Recent company news

KNSAKiniksa2026-08-07 20:01 EST

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

KNSAKiniksa2026-07-28 11:30 EST

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-07-23 20:01 EST

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

KNSAKiniksa2026-04-28 11:30 EST

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

Stock data

Close
76.51 USD
Market cap
3.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States